Clinical Trial Update: BCX-1777 in Treating Patients With Refractory Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial of BCX-1777 in patients with refractory cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• BCX-1777 (BCX-1777)

Snippet

Sponsor: BioCryst Pharmaceuticals | Conditions: Cancer | Phase 1 | Status: COMPLETED